Formoterol and Salmeterol in Partially Reversible Chronic Obstructive Pulmonary Disease: A Crossover, Placebo-Controlled Comparison of Onset and Duration of Action

Publisher： Karger

E-ISSN： 1423-0356|66|5|434-439

ISSN： 0025-7931

Source： Respiration, Vol.66, Iss.5, 1999-09, pp. : 434-439

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of the Bronchodilating Effect of Salmeterol and Zafirlukast in Combination with That of Their Use as Single Treatments in Asthma and Chronic Obstructive Pulmonary Disease

By  

Respiration, Vol. 68, Iss. 5, 2001-10 ,pp. : 452-459

Karger

Access to resources Recommend Favorite

Effects of Almitrine Bismesylate on Arterial Blood Gases in Patients with Chronic Obstructive Pulmonary Disease and Moderate Hypoxaemia: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Study

By  

Respiration, Vol. 70, Iss. 3, 2003-08 ,pp. : 275-283

Karger

Access to resources Recommend Favorite

Effects of Salmeterol on Sleeping Oxygen Saturation in Chronic Obstructive Pulmonary Disease

By  

Respiration, Vol. 79, Iss. 6, 2009-08 ,pp. : 475-481

Karger

Access to resources Recommend Favorite

Should the Choice of a Long-Acting Bronchodilator in the Long-Term Therapy of Chronic Obstructive Pulmonary Disease Depend Entirely on the Onset of Action?

By  

Respiration, Vol. 73, Iss. 4, 2006-07 ,pp. : 410-411

Karger

Access to resources Recommend Favorite

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

By Rutten-van Mölken Maureen   Oostenbrink Jan   Miravitlles Marc   Monz Brigitta  

The European Journal of Health Economics, Vol. 8, Iss. 2, 2007-06 ,pp. : 123-135

Springer Publishing Company

Access to resources Recommend Favorite